

CBE ID

1878

Title

HER2 testing for overexpression or gene amplification in patients with breast cancer

Project

Cancer

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Fall 2020

Removal Date

Sun, 11/01/2020 - 19:00

Initial Endorsement

Mon, 10/22/2012 - 08:01

Steward

American Society of Clinical Oncology

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

Proportion of female patients (aged 18 years and older) with breast cancer who receive human epidermal growth factor receptor 2 (HER2) testing for overexpression or gene amplification

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice

1.9 Care Setting

Outpatient Services

1.14 Numerator

HER2 testing performed

1.15 Denominator

Adult women with breast cancer

1.20 Types of Data Sources

Registry data

6.1.2 Current or Planned Use(s)

Payment Program, Professional Certification or Recognition Program, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

6.1.3 Current Use(s)

Payment Program, Professional Certification or Recognition Program, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Exclusions

None

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

American Society of Clinical Oncology

Steward POC email

Tayyaba.Shehzadi@asco.org